AbbVie | Pharmaceutical Development Pipeline Skip to main content

Explore Our Pipeline

We're tackling diseases where there is a significant patient need for more and better solutions, with our focus on hepatitis C, immune-mediated conditions, cancer and more. Our scientists are working to advance a pipeline of specialty medicines that demonstrate both strong clinical performance and economic value.

Our expertise in both small molecules and biologics allows us to find and pursue the best solution for a given disease.

Therapeutic Areas

Oncology

Phase 1

Phase 2

Phase 3

Submitted

Approved

ABBV-075

Overview

ABBV-075 is a small molecule Bromodomain and Extra-Terminal motif (BET) inhibitor being studied in a Phase 1 clinical trial in patients with advanced hematologic malignancies and solid tumors.

Type of Molecule

Small Molecule

Target

BET

Acute Myeloid Leukemia (AML)
PH 1
Multiple Myeloma (MM)
PH 1
Solid Tumors
PH 1

ABBV-085

Overview

ABBV-085 is an antibody drug conjugate (ADC) being investigated to treat advanced solid tumors.

Type of Molecule

Antibody Drug Conjugate (ADC)

Target

LRRC15

Solid Tumors
PH 1

ABBV-221

Overview

ABBV-221 is an antibody drug conjugate (ADC) targeting EGFR that is being investigated to treat cancerous tumors.

Type of Molecule

Antibody Drug Conjugate (ADC)

Target

EGFR

Solid Tumors
PH 1

ABBV-399

Overview

ABBV-399 is an antibody drug conjugate (ADC) targeting cMet that is being investigated to treat solid cancer tumors.

Type of Molecule

Antibody Drug Conjugate (ADC)

Target

cMet

Solid Tumors
PH 1

ABBV-838

Overview

ABBV-838 is an antibody drug conjugate (ADC) targeting CS1 that is being investigated to treat multiple myeloma.

Type of Molecule

Antibody Drug Conjugate (ADC)

Target

CS1

Multiple Myeloma (MM)
PH 1

ABT-165

Overview

ABT-165 is Dual Variable Domain Immunoglobulin (DVD) targeting DLL4 and VEGF, being investigated to treat solid tumors.

Type of Molecule

Dual Variable Domain Immunoglobulin (DVD)

Target

DLL4/VEGF

Solid Tumors
PH 1

ABT-414

Overview

ABT-414 is an antibody drug conjugate (ADC) targeting EGFR that is being investigated to treat 1L and 2L glioblastoma (GBM) and solid tumors.

Type of Molecule

Antibody Drug Conjugate (ADC)

Target

EGFR

Glioblastoma (GBM)
PH 2
Pediatric Brain Tumors
PH 1

ABT-RTA 408

Overview

ABT-RTA 408 is a small molecule Nrf-2 activator being invesitgated to treat multiple cancers. It is being developed in conjunction with Reata.

Type of Molecule

Small Molecule

Target

Nrf-2

Melanoma
PH 1

Empliciti

Overview

Empliciti (elotuzumab) is a monoclonal antibody targeting SLAMF7, approved to treat multiple myeloma.

Type of Molecule

Monoclonal Antibody

Target

SLAMF7

Region Target

US, EU, Japan (Submitted)

Multiple Myeloma (MM)
Approved
Multiple Myeloma (MM) Treatment Naïve
PH 3

Imbruvica

Overview

IMBRUVICA® (ibrutinib) is a Bruton’s tyrosine kinase (BTK) inhibitor currently being evaluated in multiple types of cancer and for other serious diseases.

Type of Molecule

Small molecule

Target

BTK

Solid Tumors
PH 2
Multiple Myeloma (MM)
PH 2
Acute Myeloid Leukemia (AML)
PH 2
Diffuse Large B-cell Lymphoma (DLBCL)
PH 2
Follicular Lymphoma (FL)
PH 2
Marginal Zone Lymphoma (MZL)
PH 2
Chronic Graft versus Host Disease (cGVHD)
PH 2
Chronic Lymphocytic Leukemia (CLL)
Approved
Waldenstrӧm's Macroglobulinemia (WM)
Approved
Mantle Cell Lymphoma (MCL)
Approved

Rova –T

Overview

Rova-T (rovalpituzumab tesirine) is an investigational antibody drug conjugate targeting the cancer stem cell-associated target delta-like protein 3 (DLL3). It is also being investigated as a combination therapy with Bristol-Myers Squibb’s Opdivo (nivolumab) and Opdivo + Yervoy (ipilimumab) regimen as a second-line treatment for extensive-stage small cell lung cancer (SCLC).

Type of Molecule

Antibody Drug Conjugate (ADC)

Target

DLL3

Small Cell Lung Cancer (SCLC)
PH 2
Solid Tumors
PH 1

Veliparib

Overview

Veliparib (ABT-888) is a PARP inhibitor being investigated to treat squamous and non-squamous non-small cell lung cancer, BRCA breast cancer, ovarian cancer and neoadjuvant breast cancer.

Type of Molecule

Small Molecule

Target

PARP

Small Cell Lung Cancer (SCLC)
PH 1
Colorectal
PH 2
Squamous Non-Small Cell Lung Cancer (sqNSCLC)
PH 3
Non-squamous Non-Small Cell Lung Cancer (NsqSCLC)
PH 3
Breast (BRCA)
PH 3
Ovarian
PH 3
Triple Negative Breast Cancer (TNBC)
PH 3

Venclexta

Overview

Venclexta (ABT-199) is a selective small molecule Bcl-2 inhibitor being investigated for the treatment of multiple cancers.

Type of Molecule

Small Molecule

Target

Bcl-2

Acute Myeloid Leukemia (AML)
PH 2
Diffuse Large B-Cell Lymphoma (DLBCL)
PH 2
Non-Hodgkin Lymphoma (NHL)
PH 2
Multiple Myeloma (MM)
PH 3
Chronic Lymphocytic Leukemia (CLL)
PH 3
Chronic Lymphocytic Leukemia (CLL) with 17p deletion (US - Approved; EU - Submitted)
Approved

Immunology

Phase 1

Phase 2

Phase 3

Submitted

Approved

ABBV-323

Overview

ABBV-323 is an antagonist to CD40 being investigated to treat Crohn’s Disease.

Type of Molecule

Biologic

Target

CD40

Crohn's Disease (CD)
PH 1

ABT-494

Overview

ABT-494 is a JAK1 selective inhibitor being investigated to treat rheumatoid arthritis, Crohn's disease, ulcerative colitis and psoriatic arthritis.

Type of Molecule

Small Molecule

Target

JAK1

Atopic Dermatitis
PH 1
Crohn's Disease (CD)
PH 2
Rheumatoid Arthritis (RA)
PH 3
Ulcerative Colitis
PH 2

ABT-981

Overview

ABT-981 is a Dual Variable Domain Immunoglobulin (DVD) IL-1 alpha/beta antagonist being investigated for the treatment of osteoarthritis.

Type of Molecule

Dual Variable Domain Immunoglobulin (DVD)

Target

IL-1 α/β

Erosive Hand Osteoarthritis (OA)
PH 2
Knee Osteoarthritis (OA)
PH 2

ALX-0061

Overview

ALX-0061 is a monoclonal antibody IL-6 receptor antagonist being investigated for the treatment of rheumatoid arthritis in collaboration with Ablynx.

Type of Molecule

Monoclonal Antibody

Target

IL-6 receptor

Lupus Erythematosus
PH 2
Rheumatoid Arthritis (RA)
PH 2

HUMIRA

Overview

Humira currently treats Crohn's disease, rheumatoid arthritis, ulcerative colitis, hidradenitis suppurativa, psoriasis, psoriatic arthritis, juvenile idiopathic arthritis, ankylosing spondylitis and uveitis (US, EU). Humira remains under investigation to treat uveitis (Japan).

Type of Molecule

Monoclonal Antibody

Target

TNF

Uveitis (US, EU - Approved; JAPAN - Submitted)
Approved
Hidradenitis Suppurativa (HS) (US, EU)
Approved

Risankizumab

Overview

Risankizumab (ABBV-066) is anti-IL-23 antibody being investigated for the treatment of multiple inflammatory diseases, including psoriasis, Crohn's disease and psoriatic arthritis.

Type of Molecule

Monoclonal Antibody

Target

IL-23

Crohn's disease
PH 2
Psoriatic Arthritis
PH 2
Psoriasis
PH 3

Neuroscience

Phase 1

Phase 2

Phase 3

Submitted

Approved

ABBV-8E12

Overview

ABBV-8E-12 is a anti-tau antibody being investigated to treat Alzheimer's disease and Progressive Supranuclear Palsy (PSP).

Type of Molecule

Monoclonal Antibody

Target

Tau

Progressive Supranuclear Palsy
PH 1
Alzheimer's Disease (AD)
- -

ABT-555

Overview

ABT-555 is a monoclonal antibody RGMa inhibitor being investigated to treat spinal cord injuries and multiple sclerosis.

Type of Molecule

Monoclonal Antibody

Target

RGMa

Multiple Sclerosis (MS)
PH 1
Spinal Cord Injury
- -

ABT-RTA 408

Overview

ABT-RTA 408 is a small molecule Nrf-2 activator being invesitgated to treat Mitochondrial Myopathy and Friedreich's Ataxia. It is being developed in collaboration with Reata.

Type of Molecule

Small Molecule

Target

Nrf-2

Mitochondrial Myopathy
PH 2
Friedreich’s Ataxia
PH 2

Duodopa

Overview

Duodopa (ABT-SLV187) is a first line therapy for advanced Parkinson's disease patients with severe motor fluctuations, when conventional oral therapy is not effective.

Type of Molecule

Small Molecule

Target

Dopamine

Region

Approved in US (Duopa), EU and Japan

Parkinson's
Approved

Duodopa NexGen

Overview

Duodopa NexGen is a combination system with a smaller, lighter infusion pump and other features for an improved patient experience.

Type of Molecule

Small Molecule

Target

Dopamine

Parkinson's
PH 3

Zinbryta

Overview

Zinbryta (ABT-803) is a CD25 antagonist antibody therapy being investigated for relapsing forms of multiple sclerosis.

Type of Molecule

Monoclonal Antibody

Target

CD25

Region

US, EU

Multiple Sclerosis (MS)
Approved

Virology

Phase 1

Phase 2

Phase 3

Submitted

Approved

HCV Next Gen

Overview

HCV Next Gen is a once-daily coformulated next generation HCV treatment including the HCV NS5A inhibitor (ABT-530) and ABT-493 (broad-genotypic NS3/4A protease inhibitor).

Type of Molecule

Small Molecule

Target

Protease/NS5A

Hepatitis C
PH 3

Exviera

Overview

EXVIERA (dasabuvir) is licensed for use with or without ribavirin (RBV) for the treatment of genotype 1 chronic HCV infection, and also for use with RBV in non-cirrhotic, genotype 4 chronic hepatitis C.

Type of Molecule

Small Molecule

Target

Polymerase

Region

EU

Hepatitis C
Approved

Technivie

Overview

TECHNIVIE is a fixed-dose combination of ombitasvir, a HCV NS5A inhibitor, paritaprevir, a HCV NS3/4A protease inhibitor, and ritonavir, a CYP3A inhibitor and is indicated in combination with ribavirin for the treatment of genotype 4 chronic HCV infection without cirrhosis.

Type of Molecule

Small Molecule

Region

US

Hepatitis C
Approved

Viekirax

Overview

VIEKIRAX (ombitasvir/paritaprevir/ritonavir) is licensed for use with or without ribavirin (RBV) for the treatment of genotype 1 chronic HCV infection, and also for use with RBV in non-cirrhotic, genotype 4 chronic hepatitis C.

Type of Molecule

Small Molecule

Region

EU, Japan

Hepatitis C
Approved

Viekira Pak

Overview

VIEKIRA PAK with or without ribavirin is indicated for the treatment of genotype 1 chronic HCV infection including with compensated cirrhosis. VIEKIRA PAK includes ombitasvir, a HCV NS5A inhibitor, paritaprevir, a HCV NS3/4A protease inhibitor, ritonavir, a CYP3A inhibitor and dasabuvir, a HCV non-nucleoside NS5B polymerase inhibitor.

Type of Molecule

Small Molecule

Region

US

Hepatitis C
Approved

Viekira XR

Overview

Viekira XR is a co-formulated QD dasabuvir/ombitasvir/paritaprevir/ritonavir tablet approved to treat genotype 1 chronic HCV infection in the United States.

Type of Molecule

Small Molecule

Target

Protease/NS5A

Region

US, EU

Hepatitis C (US-Approved, EU-Submitted)
Approved

General Medicine

Phase 1

Phase 2

Phase 3

Submitted

Approved

ABBV-974

Overview

ABBV-974 is a CFTR potentiator being studied for the treatment of cystic fibrosis (CF).

Type of Molecule

Small Molecule

Target

CTFR

Cystic Fibrosis
PH 1

ABBV-2222

Overview

ABBV-2222 is a CFTR corrector being studied for the treatment of cystic fibrosis (CF).

Type of Molecule

Small Molecule

Target

CTFR

Cystic Fibrosis
PH 1

ABBV-2451

Overview

ABBV-2451 is a CFTR potentiator being studied for the treatment of cystic fibrosis (CF).

Type of Molecule

Small Molecule

Target

CTFR

Cystic Fibrosis
PH 1

Atrasentan

Overview

Atrasentan (ABT-627) is an endothelin A antagonist being investigated for the treatment of diabetic nephropathy in Type 2 diabetic patients.

Type of Molecule

Small Molecule

Target

Endothelin

Diabetic Nephropathy
PH 3

Elagolix

Overview

Elagolix (ABT-620) is an oral gonadotropin-releasing hormone antagonist being studied for the treatment of endometriosis and uterine fibroids.

Type of Molecule

Small Molecule

Target

GnRH

Endometriosis
PH 3
Uterine Fibroids
PH 3

Unless otherwise specified, all product names appearing in this Internet site are trademarks owned by or licensed to AbbVie Inc., its subsidiaries or affiliates. No use of any AbbVie trademark, trade name, or trade dress in this site may be made without the prior written authorization of AbbVie Inc. except to identify the product or services of the company.